Tandem Diabetes Care, Inc. · NASDAQ:TNDM
Tandem Diabetes Care — Investor Presentation (August 2026)
27 slides from Tandem Diabetes Care's investor presentation, Aug 6, 2026
Slide 1: Company Overview
Company Overview AUGUST 6, 2026 Izzy diagnosed 2014 Ben diagnosed 2024 August 6, 2026 ››› Page 1 © 2026 Tandem Diabetes Care, Inc. All Rights Reserved
Slide 2: Disclaimers & Safe Harbor
Disclaimers & Safe Harbor CAUTIONARY NOTES REGARDING FORWARD LOOKING-STATEMENTS Certain statements in this presentation constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amende
Slide 3: Tandem Diabetes Care
Tandem Diabetes Care POSITIVELY DIFFERENT Large and underpenetrated worldwide market1 Robust portfolio offering choice and optionality o Two pump platforms: t:slim X2 and Tandem Mobi o Control-IQ+ automated insulin delivery o Compatible with leading CGM sensors Strengthening business model o U.S. -
Slide 4: Large Worldwide Market Opportunity
Large Worldwide Market Opportunity1 Persons with: US: Type 1 Diabetes ~2 Million (~40% 1.8 Pump M Penetration) US: Type 2 Insulin Intensive ~2 Million (~5% Pump Penetration) 2.3 M International: Type 1 Diabetes ~3 M (~20% Pump Penetration) 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 million People on Pumps All
Slide 5: Strategic Priorities to Drive Market Share Gains
Strategic Priorities to Drive Market Share Gains PURSUING GLOBAL LEADERSHIP IN INSULIN DELIVERY SOLUTIONS Best Performing U.S. Commercial International Patient-First Differentiated Fully Closed Loop Excellence Acceleration Channel Choices Devices Portfolio Algorithm Supported by operational efficien
Slide 6: Highly Segmented Market
PORTFOLIO APPROACH FOR Highly Segmented Market Socio- CGM Social Economic Use Support Type 1 Factors Algorithm Capability Form Factor Total Daily Dose Method Emotional Status of Device Control Discretion Age Ease of Use Time Wear Preference August 6, 2026 ››› Page 6 © 2026 Tandem Diabetes Care, Inc.
Slide 7: 2026 Market Expansion Catalysts
2026 Market Expansion Catalysts Socio- CGM Social Economic Use Support Type 1 Factors Tandem Modernized Sensor Pharmacy Type 2 Mobi Commercial Algorithm Capability Form Factor Compatibility Acceleration Diabetes System Organization Total Daily Dose Method Emotional Status of Device ↧ ↧ ↧ ↧ ↧ Control
Slide 8: Commercial Products
Commercial Products August 6, 2026 ››› Page 8 © 2026 Tandem Diabetes Care, Inc. All Rights Reserved
Slide 9: Pump Portfolio Provides Choice in AID Systems
Pump Portfolio Provides Choice in AID Systems Tandem Mobi System World's smallest, durable automated + & t:slim X2 Insulin Pump All-in-one system, color touchscreen insulin delivery system1 300-unit cartridge 200-unit cartridge Control-IQ+ Software Wireless CGM Technology Updates* Data Uploads† Comp
Slide 10: Compatible with Industry-Leading CGMs
Compatible with Industry-Leading CGMs1 t:slim X2 Pump Tandem Mobi2 Dexcom G6, G7 & G7 15 day Abbott FreeStyle Libre 2 & 3 Plus Powered by Control-IQ + technology August 6, 2026 ››› Page 10 1. CGM sold separately. CGMs shown were integrated with t:slim X2 and/or Tandem Mobi in one or more markets in
Slide 11: Control-IQ+ Technology
Control–IQ+ Technology AUTOMATED INSULIN DELIVERY (AID) PREDICTS AND HELPS PREVENT HIGHS AND LOWS TESTED TRUSTED BETTER 200+ peer-reviewed Leading outcomes with Benefits featured four times manuscripts significantly fewer adverse in The New England Journal 440,000+ pump users events of Medicine worl
Slide 12: Tandem Source
Tandem Source CLINICIANS THE GO-TO DIABETES MANAGEMENT PLATFORM Patient Engagement Reporting PATIENTS & CAREGIVERS ADMINS Patient Monitoring Data Management Clinic & Patient Support and Device Decision Support Reporting Management Software Updates Decision Support* Customer Experience Supplies Order
Slide 13: Robust Pipeline
Robust Pipeline August 6, 2026 ››› Page 13 © 2026 Tandem Diabetes Care, Inc. All Rights Reserved
Slide 14: Innovative Pipeline
Innovative Pipeline Fully closed-loop New Dual glucose-ketone AID for type 1 and insulins sensor integration type 2 diabetes FDA CLEARED SUBMITTED TO FDA – Q2’26 Tubeless Mobi with Next Generation Mobi SteadiSet extended extended wear featuring Sigi tubeless wear infusion set technology technology A
Slide 15: Continuous AID Improvement
Continuous AID Improvement GROWING THE MARKET BY REDUCING DIABETES BURDEN 2025 2026 Expanded Indications Expanded Indications (Ages 2+, T2D) (Pregnancy) 2020 Plan to begin Fully Closed Advanced Hybrid Loop pivotal trial (T1D & T2D) Closed Loop In Pursuit of . . . Fully Greater Ease of Use 2018 Close
Slide 16: Financial Information
Financial Information August 6, 2026 ››› Page 16 © 2026 Tandem Diabetes Care, Inc. All Rights Reserved
Slide 17: Q2 2026 Results
Q2 2026 Results Record Second Quarter Performance WW United States International Financials Highlights Highlights Sales of $255M* Sales of $179M* Sales of $75M* Pump shipments of Pump shipments of Pump shipments of 33,000 or 10% YoY 22,000* 11,000 Growth* Advanced PAYGO model in Multiple commercial
Slide 18: Second Quarter Performance
Second Quarter Performance Q2 Worldwide Shipments ($ in M) Q2 Worldwide Sales 35,000 33,000 $300 30,000 30,000 +10% 30,000 25,000 $255 20,000 $250 $241 +6%1 15,000 $222 10,000 5,000 0 $200 Q2'24 Q2'25 Q2'26 Q2'24 Q2'25 Q2'26 Q2 Gross Margin Q2 Adjusted EBITDA Margin2 80% 5% -1% +4.6 pts 57% -1% 3% 6
Slide 19: PayGo: Enhanced Benefit & Value Creation
PayGo: Enhanced Benefit & Value Creation Payors benefit from Healthcare Providers improved member benefit from streamlined outcomes with prescription process enhanced data visibility Pharmacy Channel PayGo reimbursement structure Customers benefit from lower out of pocket cost Manufacturers receive
Slide 20: U.S. PayGo Transition Assumptions Intact
U.S. PayGo Transition Assumptions Intact STRENGTHENING OUR BUSINESS MODEL & CREATING LONG-TERM VALUE 2026 U.S. MODELING ASSUMPTIONS DME Pharmacy No updates to modeling assumptions provided in February 2026 ~$4,000 $0 Pump ASP Upfront Began moving to PayGo pharmacy Upfront payment payment reimburseme
Slide 21: International Direct Transition Assumptions
International Direct Transition Assumptions ENHANCING PRESCRIBER RELATIONSHIPS WHILE IMPROVING PRICE AND MARGINS Transition to direct commercial operations timeline 2026 INTERNATIONAL MODELING ASSUMPTIONS • Q1’26 – Direct sales began in UK, Switzerland and Blended Pricing in $USD Austria • Plan to c
Slide 22: 2026 Guidance
2026 Guidance REAFFIRMING SALES AND MARGIN 2026 GUIDANCE1 2026 Q3’26 Worldwide Sales $1.065B - $1.085B ~$265M U.S. Shipments 94K - 95K - U.S. Sales $730M - $745M ~$180M (PayGo Assumption) (Includes $70M - $80M Headwind) International Sales $335M - $340M ~$85M (Direct Transition Assumption) (Includes
Slide 23: Longer-Term Assumptions
Longer-Term Assumptions* DRIVING TO SUSTAINED DOUBLE-DIGIT GROWTH & PROFITABILITY U.S. Sales & Channel Mix International Profitability Goals (2-3 years) ~80% of pump shipments through ASPs are anticipated to pharmacy be at least 30% higher 65%+ gross margin in individual direct ~70% of sales markets
Slide 24: Appendix: Reconciliation of GAAP to Non-GAAP Measures
Appendix Reconciliation of GAAP to Non-GAAP Measures August 6, 2026 ››› Page 24 © 2026 Tandem Diabetes Care, Inc. All Rights Reserved
Slide 25: Reconciliation
Reconciliation GAAP versus Non-GAAP Financial Results ($'s in thousands) Three Months Ended June 30, ($'s in thousands) Six Months Ended June 30, 2026 2025 2024 2026 2025 2024 GAAP sales $254,560 $240,678 $221,910 GAAP sales $501,781 $475,100 $413,584 Adjustment for Tandem Choice(1) — — (154) Adjust
Slide 26: Reconciliation
Reconciliation GAAP Reconciliation of Constant Currency Sales Growth ($'s in thousands) ($'s in thousands) Three Months Ended Six Months Ended June 30, June 30, % Change % Change Currency Constant Currency Constant 2026 2025 % Change Impact Currency 2026 2025 % Change Impact Currency United States:
Slide 27: Tandem Diabetes Care
Tandem Heena diagnosed 2021 Diabetes Care Investor Relations: Afsha 858-366-6900 diagnosed 2000 IR@tandemdiabetes.com TRADEMARKS ©2026 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, Tandem Diabetes, Tandem, Tandem Mobi, Steadiset, Tandem Source, t:slim X2, Control-IQ, Control-
Tandem Diabetes Care — Investor Presentation (August 2026) on 6ix